Exercise and Performance Nutrition Laboratory
Saint Charles, Missouri, 63301, United States
NCT Number: NCT05811923
The purpose of this study is to evaluate the acute impact of ingesting individual and combined dosages of caffeine and paraxanthine in comparison to placebo on changes in resting metabolic rate, perceived levels of affect, and markers of lipolysis.
Looking for future studies?
Notify Me18 year–39 year
All sexes
Interventional
Not applicable
Saint Charles, Missouri, 63301, United States
The study will be conducted using a randomized, double-blind, placebo-controlled, crossover study design. Approximately 10 healthy men and 10 healthy women between the ages of 18 - 39 years of age will be recruited to participate in this study. Prior to beginning the study, all participants will sign an IRB-approved informed consent document and complete a healthy history questionnaire to determine study eligibility. All participants will report to the laboratory for all study visits between 0600 - 1000 hours. Prior to each of the seven study visits, participants will be asked to abstain from exercise, tobacco, nicotine, and alcohol for 24 hours and observe an overnight (8 - 10 hours) fast including caffeine. Study visit 1 will be a screening visit where participants will first sign an IRB-approved informed consent document. To determine eligibility, participants will then complete a health and medical history form and have their height and weight assessed along with their resting heart rate and blood pressure. If determined eligible, study participants will allowed to exercise within 24 hours of each study visit. On one occasion prior to study visit 1, study participants will be required to record their food and fluid intake for the three days prior to each study visit and instructed to replicate this diet prior to each visit. To assist in replicating their food intake, participants will be given pre-packaged frozen meals of their choosing. All meals will provide similar amounts of energy, carbohydrates, fats, and proteins. Participants will be instructed to follow an overnight fast whereby no food or fluid with calories will be consumed for the 8 to 10-hour period prior to each study visit. Water intake will be encouraged during this time for appropriate hydration status. Upon arrival for each subsequent study visit, participants will again have their body mass determined and they must be determined to be weight stable (defined as having a body mass within 2% of their previous study visit body mass). Resting heart rate, blood pressure, and body composition will then be assessed (only study visit 2) using a bio-electrical impedance analyzer (BIA). After assessment of body mass, resting heart rate, and resting blood pressure, study participants will donate their first of six venous blood samples. From there, participants will complete a series of assessments evaluating various perceptual indicators using the profile of mood states (POMS) and anchored 100-mm visual analog scales. Finally, participants will then have their resting metabolic rate determined using a metabolic cart. Upon determination of baseline resting metabolic rate, participants will be assigned in a randomized, double-blind, placebo-controlled, crossover fashion to ingest one of seven supplement conditions. One condition will be a non-energetic placebo (maltodextrin) while the other six supplemental conditions will be a 200 mg dose of caffeine, 100 mg paraxanthine, 200 mg paraxanthine, 300 mg paraxanthine, a combination of caffeine (200 mg) + paraxanthine (200 mg), and a 200 mg dose of 1-methylxanthine. All supplements will be orally ingested with 8 fluid ounces of cold tap water. The order of administration for all interventions will be randomized using a random allocation software to ensure randomization and to avoid order effects. After ingestion, participants will complete all assessments in an identical fashion 30, 60, 90, 120, and 180 minutes after ingestion of their assigned supplement. All study visits will take place between 0600 - 1000 hours. It is anticipated that follow-up study visits will be scheduled 3 - 7 days apart from each other after all dietary and exercise controls have been observed.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Within each supplementation condition, study participants will have their venous blood collected on six different occasions: 0, 30, 60, 90, 120, and 180 minutes after ingestion of their assigned study agent. Blood will be collected via a forearm vein using standard phlebotomy techniques using either an indwelling catheter or single venipunctures. All blood samples will be collected into ethylenediaminetetraacetic acid EDTA-coated Vacutainer™ tubes and gently inverted ten times before being centrifuged at 3000 revolutions per minute (rpm) (MegaFuge XFR, Thermo Fisher Scientific, Waltham, MA, USA) at 4oC for 20 minutes. After centrifugation, 400 μl aliquots of plasma will be removed and frozen at -80oC within four hours of collection.
During all study visits and on six occasions during each of the seven experimental conditions (0, 30, 60, 90, 120, and 180 minutes after supplement ingestion), resting metabolic rates will be determined in a thermoneutral laboratory environment.
Participants will complete electronic versions of the Profile of Mood States (POMS) questionnaire to evaluate perceptual responses. The Profile of Mood States (POMS) is a 65-item validated scale that uses a 5-point Likert scale with each individual area being scored and summed into profiles for tension, anger, vigor, fatigue, depression, and confusion. Finally, a total mood disturbance score will be calculated by summing all categories and subtracting the vigor score.
Participants will complete electronic versions of the visual analog (VAS) scale to evaluate perceptual responses. Each VAS scale will be completed using a 100-mm line anchored by "Lowest Possible" and "Highest Possible" to assess subjective ratings of focus, anxiety, concentration, energy, restfulness, wakefulness, swagger, confidence, hunger, and appetite. The validity and reliability of VAS to assess fatigue and energy have been previously established (Lee, Hicks, et al. 1991) and our methods have been published elsewhere (Ziegenfuss, Habowski, et al. 2017, Ziegenfuss, Lopez, et al. 2017, Ziegenfuss, Kedia, et al. 2018, Zabriskie, Blumkaitis, et al. 2020).
Time frame: 3 hours
During all study visits and on six occasions during each of the seven experimental conditions (0, 30, 60, 90, 120, and 180 minutes after supplement ingestion), resting metabolic rates will be determined in a thermoneutral laboratory environment. To complete each assessment, participants will rest supine with a blanket placed over them in an environment free of auditory and visual stimuli. A clear, hard plastic shield with a transparent plastic drape will be placed over the participant's head and shoulder and connected to the metabolic cart to collect all expired gases (oxygen and carbon dioxide). All expired gases will be analyzed using indirect calorimetry (TrueMax 2400 Metabolic Measurement System, ParvoMedics, Sandy, UT, USA) and computed to determine rates of energy expenditure
Time frame: 3 hours
During all study visits and on six occasions during each of the seven experimental conditions (0, 30, 60, 90, 120, and 180 minutes after supplement ingestion), resting metabolic rates will be determined in a thermoneutral laboratory environment. To complete each assessment, participants will rest supine with a blanket placed over them in an environment free of auditory and visual stimuli. A clear, hard plastic shield with a transparent plastic drape will be placed over the participant's head and shoulder and connected to the metabolic cart to collect all expired gases (oxygen and carbon dioxide). All expired gases will be analyzed using indirect calorimetry (TrueMax 2400 Metabolic Measurement System, ParvoMedics, Sandy, UT, USA) and computed to determine rates of energy expenditure
Time frame: 3 hours
Participants will complete electronic versions of the Profile of Mood States (POMS) questionnaire and visual analog (VAS) scale to evaluate perceptual responses. Each VAS scale will be completed using a 100-mm line anchored by "Lowest Possible" and "Highest Possible" to assess subjective ratings of focus, anxiety, concentration, energy, restfulness, wakefulness, swagger, confidence, hunger, and appetite. 0 is lowest level and 5 is highest level.
Time frame: 3 hours
During all study visits and on six occasions during each of the seven experimental conditions (0, 30, 60, 90, 120, and 180 minutes after supplement ingestion), resting metabolic rates will be determined in a thermoneutral laboratory environment. To complete each assessment, participants will rest supine with a blanket placed over them in an environment free of auditory and visual stimuli. A clear, hard plastic shield with a transparent plastic drape will be placed over the participant's head and shoulder and connected to the metabolic cart to collect all expired gases (oxygen and carbon dioxide). All expired gases will be analyzed using indirect calorimetry (TrueMax 2400 Metabolic Measurement System, ParvoMedics, Sandy, UT, USA) and computed to determine rates of carbohydrate and fat oxidation in response to supplement ingestion
Time frame: 3 hours
The collected blood will be analyzed using a hand-held glucose analyzer and fasting will be considered confirmed if glucose is < 110 mg/dL. Within each supplementation condition, study participants will have their venous blood collected on six different occasions: 0, 30, 60, 90, 120, and 180 minutes after ingestion of their assigned study agent
Time frame: 3 hours
Resting heart rate (bpm) measured at all 6 time points over 180 minutes
Time frame: 3 hours
Systolic blood pressure (mmHg) are measured at all 6 time points across 180 minutes
Time frame: 3 hours
Diastolic blood pressure (mmHg) are measured at all 6 time points across 180 minutes
Time frame: 3 hours
Adverse events are self-reported at all study visits and all time-points
Lindenwood University
Other
Acronym: PX
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04057339
Behavior, Fasting
La Jolla, California, United States
View Trial DetailsNCT07702669
Glucose Metabolism Disorders, Hyperinsulinism
Harbin, Heilongjiang, China
View Trial DetailsNCT06461273
Behavior, Body Weight
Newark, New Jersey, United States
View Trial DetailsNCT06186102
Arterial Occlusive Diseases, Arteriosclerosis
Aarhus, Jutland, Denmark
View Trial Details